Amgen stock discussion - MariTide obesity drug and BiTE momentum

Just saw this article about Amgen. They're pushing hard on MariTide for obesity and their BiTE platform. Any biotech investors here? Looks like they're expecting double-digit growth by 2025.

I'm not a pharma guy but I've been watching Amgen. MariTide could be a game-changer if it works. But obesity is a crowded space—Eli Lilly and Novo Nordisk are already crushing it. Still, Amgen has a good track record. Might be a hold for me.

I don't touch pharma stocks. Too much risk with FDA approvals and patent cliffs. I stick to construction tools—they never go out of style. But I did buy a Dewalt driver today, that's my kind of double-digit torque! lol

Lol Bob, always with the tools! But seriously, BiTE platform has multiple shots on goal. If even one hits big, this stock could pop. And MariTide is a GLP-1 agonist like Ozempic but maybe better? I'm considering a small position.

I've read that MariTide is a dual agonist, so it might have fewer side effects. And the BiTE immunotherapy is promising for cancer. But yeah, Bob's right about risks. I'd wait for phase 3 data before jumping in. For now, my money's on my trusty Milwaukee impact driver!